Efficacy of Blood Pressure-Lowering Pharmacotherapy in Isolated Diastolic Hypertension: A Systematic Synthesis of Evidence

Highlights

• Individual participant data (IPD) meta-analysis reveals that a 5 mmHg reduction in systolic blood pressure (SBP) reduces major cardiovascular events (MACE) by approximately 9% in patients with isolated diastolic hypertension (IDH), matching the efficacy seen in other hypertension phenotypes.
• IDH is an independent risk factor for adverse outcomes, including heart failure, myocardial infarction, stroke, and a significantly elevated risk (HR 1.67) for incident aortic aneurysms.
• Clinical benefits of pharmacotherapy do not diminish in patients with low baseline diastolic blood pressure (DBP < 60 mmHg), providing evidence against withholding treatment solely due to DBP concerns.
• While the prevalence of IDH is lower than isolated systolic hypertension (ISH), its contribution to cardiovascular risk is more pronounced in younger populations, where diagnosis and treatment rates often remain suboptimal.

Background

Historically, clinical focus has prioritized systolic blood pressure (SBP) as the primary driver of cardiovascular disease (CVD) risk, particularly in older populations where isolated systolic hypertension (ISH) predominates due to arterial stiffening. However, the clinical significance of isolated diastolic hypertension (IDH)—defined as elevated diastolic blood pressure (DBP) in the presence of normal SBP—has been a subject of ongoing debate. The 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines intensified this discussion by lowering the hypertension threshold to 130/80 mmHg, significantly increasing the prevalence of IDH.

Clinicians often face a therapeutic dilemma in IDH: whether the potential benefits of lowering DBP outweigh the risks of further reducing SBP in patients whose SBP is already within a “normal” range. Until recently, randomized controlled trial (RCT) data specifically addressing the efficacy of pharmacotherapy in the IDH phenotype were sparse. This review synthesizes high-quality evidence, including a recent large-scale individual participant data meta-analysis, to clarify the risk-benefit profile of BP-lowering therapy in this population.

Key Content

The Epidemiological Burden and Risk Profile of IDH

Recent large-scale observational studies underscore that IDH is far from benign. Analysis of the Japan Medical Data Center database (n=1,746,493) demonstrated that both Stage 1 IDH (DBP 80–89 mmHg) and Stage 2 IDH (DBP ≥90 mmHg) are independently associated with an increased incidence of myocardial infarction, angina, and stroke. Similarly, a cohort study in China (n=430,977) found that IDH was associated with a hazard ratio (HR) of 2.20 for CVD mortality compared to normotensive individuals.

Notably, IDH appears to have unique associations with specific vascular pathologies. Data from the UK Biobank cohort (n=397,019) revealed that elevated DBP is a more potent predictor of incident thoracic and abdominal aortic aneurysms (AA) than SBP. Participants with IDH exhibited an HR of 1.67 for AA, significantly higher than those with ISH. This suggests that the mechanical stress imposed by elevated diastolic pressure may play a specialized role in the degradation of the aortic wall.

The 2026 Landmark Meta-Analysis: Clinical Efficacy of BP Lowering

A pivotal individual participant data (IPD) meta-analysis published in 2026 (Bavishi et al., Eur Heart J) provided definitive evidence regarding treatment efficacy. Pooling data from 51 RCTs comprising 358,325 participants, researchers compared treatment effects in those with IDH (SBP < 130 and DBP ≥ 80 mmHg) versus those without.

Key findings from this meta-analysis include:

• Uniform Risk Reduction: A 5 mmHg reduction in SBP yielded a similar relative risk reduction for major cardiovascular events in IDH patients (HR 0.91; 95% CI, 0.82-1.01) and non-IDH patients (HR 0.90; 95% CI, 0.89-0.92).
• Consistency Across DBP Tiers: There was no evidence of heterogeneity in treatment effects across baseline DBP categories. Crucially, the benefits did not diminish even in patients with baseline DBP < 60 mmHg.
• Phenotypic Stability: The relative treatment effects remained consistent regardless of age, sex, CVD history, or prior medication use.

Phenotypic Differences: IDH vs. ISH vs. SDH

The relationship between hypertension subtypes and heart failure (HF) appears to be age-dependent. Data from the Cardiovascular Health Study and other large cohorts indicate that while ISH is common in the elderly and a strong risk factor for HF, IDH also contributes significantly to HF risk, particularly in younger and middle-aged adults. In a study of over 2.6 million people, the hazard ratios for HF associated with IDH, ISH, and combined systolic-diastolic hypertension (SDH) all decreased with advancing age, suggesting that early intervention in IDH may yield the greatest long-term preventive benefit.

Regarding therapeutic response, some studies have suggested that ISH—often a marker of advanced atherosclerosis and vascular stiffness—may be less responsive to certain interventions like catheter-based renal denervation (RDN). Initial reports from the SYMPLICITY HTN-3 and RADIANCE-HTN SOLO trials suggested reduced BP-lowering effects in ISH compared to CH. However, when adjusted for baseline BP values and age, the relative efficacy of RDN appears more balanced across phenotypes, although vascular compliance remains a limiting factor in the ISH subgroup.

Methodological Advances in Hypertension Diagnosis

The transition from the 140/90 mmHg threshold to 130/80 mmHg has fundamentally shifted the constituent ratio of hypertension phenotypes. Studies focusing on newly diagnosed patients show that the 130/80 mmHg criteria nearly doubled the prevalence of hypertension in certain cohorts and significantly increased the proportion of patients diagnosed with SDH and IDH. This shift emphasizes the need for clinicians to move beyond simple systolic targets and consider the global hemodynamic profile of the patient.

Expert Commentary

Addressing the “J-Curve” Concern

A perennial concern in hypertension management is the “J-curve” phenomenon, where excessively lowering DBP might compromise coronary perfusion, which occurs primarily during diastole. However, the 2026 IPD meta-analysis provides a reassuring counter-narrative: relative risk reductions for MACE were maintained even down to baseline DBP levels below 60 mmHg. This suggests that in the context of modern pharmacotherapy, the protective effects of systemic BP reduction generally outweigh the theoretical risks of low DBP, provided the reduction is achieved through standardized, evidence-based regimens.

Mechanistic Insights

Mechanistically, IDH in younger patients often reflects high peripheral resistance and sympathetic overactivity, whereas ISH in the elderly reflects arterial stiffening and increased pulse wave velocity. The finding that BP-lowering drugs (primarily thiazides, ACE inhibitors, and calcium channel blockers) work equally well in IDH suggests that the reduction in global systemic vascular resistance and afterload is beneficial regardless of whether the baseline elevation was primarily systolic or diastolic.

Clinical Applicability and Guidelines

Current guidelines increasingly move toward a risk-based approach rather than relying solely on BP numbers. In a patient with IDH, the decision to initiate therapy should be guided by their total 10-year atherosclerotic cardiovascular disease (ASCVD) risk. However, the data summarized here suggest that if the decision to treat is made, the clinician can expect a similar proportional benefit in event reduction as they would in a patient with classic systolic hypertension.

Conclusion

The paradigm that isolated diastolic hypertension requires less aggressive management than systolic hypertension is increasingly challenged by robust clinical evidence. The landmark 2026 IPD meta-analysis confirms that pharmacological BP lowering reduces major CV events to a similar extent in IDH and non-IDH populations. Given that IDH is a significant risk factor for aortic aneurysms and heart failure—particularly in younger adults—clinicians should prioritize the identification and management of this phenotype. Future research should focus on whether specific drug classes (e.g., vasodilatory beta-blockers vs. RAS inhibitors) offer preferential benefits in the IDH phenotype and on improving the suboptimal treatment rates currently observed in younger IDH patients.

References

• Bavishi C, ACP Journal Club Editorial Team at McMaster University. BP-lowering drugs reduced major CV events to a similar extent in patients with or without isolated diastolic hypertension. Ann Intern Med. 2026-04-07. PMID: 41941743.
• Bavishi C, et al. Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis. Eur Heart J. 2026;47(14):1649-1657. PMID: 41384429.
• Musini VM, et al. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database Syst Rev. 2025;10(10):CD000028. PMID: 41065416.
• Li Z, et al. Association analysis of blood pressure with incident risks for thoracic and abdominal aortic aneurysms: an observational study of the UK Biobank cohort. Open Heart. 2025;12(2):e003240. PMID: 40858353.
• Kaneko H, et al. Age-Dependent Relationship of Hypertension Subtypes With Incident Heart Failure. J Am Heart Assoc. 2022;11(9):e025406. PMID: 35475350.
• Qi J, et al. Association between blood pressure categories and cardiovascular disease mortality in China. PLoS One. 2021;16(7):e0255373. PMID: 34329344.
• Ito S, et al. Association of Isolated Diastolic Hypertension Based on the Cutoff Value in the 2017 ACC/AHA BP Guidelines With Subsequent Cardiovascular Events. J Am Heart Assoc. 2020;9(19):e017963. PMID: 32993440.